A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 189,103 shares of KURA stock, worth $1.69 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
189,103
Holding current value
$1.69 Million
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.57 - $23.23 $3.51 Million - $4.39 Million
189,103 New
189,103 $3.7 Million
Q1 2023

May 15, 2023

BUY
$10.71 - $14.6 $122,393 - $166,848
11,428 New
11,428 $139,000
Q4 2020

Feb 16, 2021

SELL
$29.0 - $41.62 $4.64 Million - $6.66 Million
-159,936 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$16.3 - $30.64 $296,073 - $556,544
-18,164 Reduced 10.2%
159,936 $4.9 Million
Q2 2020

Aug 14, 2020

BUY
$7.95 - $18.81 $1.42 Million - $3.35 Million
178,100 New
178,100 $2.9 Million
Q1 2020

May 15, 2020

SELL
$6.45 - $14.04 $1.03 Million - $2.24 Million
-159,612 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$12.97 - $15.94 $2.07 Million - $2.54 Million
159,612 New
159,612 $2.2 Million
Q4 2018

Feb 14, 2019

SELL
$10.6 - $17.49 $4.01 Million - $6.61 Million
-377,952 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$16.65 - $21.85 $4.09 Million - $5.36 Million
245,406 Added 185.15%
377,952 $6.61 Million
Q2 2018

Aug 14, 2018

BUY
$14.8 - $18.8 $1.96 Million - $2.49 Million
132,546 New
132,546 $2.41 Million
Q1 2018

May 15, 2018

SELL
$14.5 - $23.4 $2.51 Million - $4.05 Million
-173,200 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$13.5 - $16.65 $2.34 Million - $2.88 Million
173,200
173,200 $2.65 Million

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $598M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.